Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2006

01.05.2006

Hepatic Resection for Metastatic Melanoma: Distinct Patterns of Recurrence and Prognosis for Ocular Versus Cutaneous Disease

verfasst von: Timothy M. Pawlik, MD, MPH, Daria Zorzi, MD, Eddie K. Abdalla, MD, Bryan M. Clary, MD, Jeffrey E. Gershenwald, MD, Merrick I. Ross, MD, Thomas A. Aloia, MD, Steven A. Curley, MD, Luis H. Camacho, MD, MPH, Lorenzo Capussotti, MD, Dominique Elias, MD, Jean-Nicolas Vauthey, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

Resection of melanoma metastatic to the liver remains controversial. We evaluated the efficacy of hepatic resection in patients with metastatic ocular and cutaneous melanoma and assessed factors that could affect survival after resection.

Methods

Forty patients with hepatic melanoma metastasis underwent resection at four major hepatobiliary centers. Clinicopathologic factors were evaluated with regard to recurrence and survival by using χ2 and log-rank tests.

Results

The primary tumor was ocular in 16 patients and cutaneous in 24. The median disease-free interval from the time of primary tumor treatment to hepatic metastasis was the same for both groups (ocular, 62.9 months; cutaneous, 63.1 months; P = .94). Most patients underwent either an extended hepatic resection (37.5%) or hemihepatectomy (22.5%). Twenty-six patients (65%) received perioperative systemic therapy. Thirty (75.0%) of 40 patients developed tumor recurrence. The median time to recurrence after hepatic resection was 8.3 months (ocular, 8.8 months; cutaneous, 4.7 months; P = .3). Patients with primary ocular melanoma were more likely to experience recurrence within the liver (53.3% vs. 17.4%; P = .015), whereas patients with a cutaneous primary tumor more often developed extrahepatic involvement. The 5-year survival rate for patients with a primary ocular melanoma was 20.5%, whereas there were no 5-year survivors for patients with cutaneous melanoma (P = .03).

Conclusions

Patterns of recurrence and prognosis after resection of hepatic melanoma metastasis differ depending on whether the primary melanoma is ocular or cutaneous. Resection should be performed as part of a multidisciplinary approach, because recurrence is common.
Literatur
1.
Zurück zum Zitat Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8–29PubMed Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8–29PubMed
2.
Zurück zum Zitat Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110:956–61PubMed Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003; 110:956–61PubMed
3.
Zurück zum Zitat Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992; 28:45–9PubMed Reintgen DS, Cox C, Slingluff CL Jr, Seigler HF. Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 1992; 28:45–9PubMed
4.
Zurück zum Zitat Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998; 67:228–33CrossRefPubMed Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998; 67:228–33CrossRefPubMed
5.
Zurück zum Zitat Becker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002; 87:840–5PubMed Becker JC, Terheyden P, Kampgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002; 87:840–5PubMed
6.
Zurück zum Zitat Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 2004; 86:172–8CrossRefPubMed Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol 2004; 86:172–8CrossRefPubMed
7.
Zurück zum Zitat Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol 1999; 38:549–57PubMed Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol 1999; 38:549–57PubMed
8.
Zurück zum Zitat Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004; 11:290–7CrossRefPubMed Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004; 11:290–7CrossRefPubMed
9.
Zurück zum Zitat Soni S, Lee DS, DiVito J Jr, et al. Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide. J Pediatr Hematol Oncol 2002; 24:488–91CrossRefPubMed Soni S, Lee DS, DiVito J Jr, et al. Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide. J Pediatr Hematol Oncol 2002; 24:488–91CrossRefPubMed
10.
Zurück zum Zitat Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622–34PubMed Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19:3622–34PubMed
11.
Zurück zum Zitat Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181:193–201PubMed Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181:193–201PubMed
12.
Zurück zum Zitat Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 1992; 36:429–38PubMed Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 1992; 36:429–38PubMed
13.
Zurück zum Zitat Pyrhonen S. The treatment of metastatic uveal melanoma. Eur J Cancer 1998;34(Suppl 3):S27–30PubMed Pyrhonen S. The treatment of metastatic uveal melanoma. Eur J Cancer 1998;34(Suppl 3):S27–30PubMed
14.
Zurück zum Zitat Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 2002; 29:413–26CrossRefPubMed Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 2002; 29:413–26CrossRefPubMed
15.
Zurück zum Zitat Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745–51PubMed Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745–51PubMed
16.
Zurück zum Zitat Duh EJ, Schachat AP, Albert DM, Patel SM. Long-term survival in a patient with uveal melanoma and liver metastasis. Arch Ophthalmol 2004; 122:285–7CrossRefPubMed Duh EJ, Schachat AP, Albert DM, Patel SM. Long-term survival in a patient with uveal melanoma and liver metastasis. Arch Ophthalmol 2004; 122:285–7CrossRefPubMed
17.
Zurück zum Zitat Mondragon-Sanchez R, Barrera-Franco JL, Cordoba-Gutierrez H, Meneses-Garcia A. Repeat hepatic resection for recurrent metastatic melanoma. Hepatogastroenterology 1999; 46:459–61PubMed Mondragon-Sanchez R, Barrera-Franco JL, Cordoba-Gutierrez H, Meneses-Garcia A. Repeat hepatic resection for recurrent metastatic melanoma. Hepatogastroenterology 1999; 46:459–61PubMed
18.
Zurück zum Zitat Gunduz K, Shields JA, Shields CL, Sato T, Mastrangelo MJ. Surgical removal of solitary hepatic metastasis from choroidal melanoma. Am J Ophthalmol 1998; 125:407–9CrossRefPubMed Gunduz K, Shields JA, Shields CL, Sato T, Mastrangelo MJ. Surgical removal of solitary hepatic metastasis from choroidal melanoma. Am J Ophthalmol 1998; 125:407–9CrossRefPubMed
19.
Zurück zum Zitat Vauthey JN, Winter MW, Blumgart LH. Solitary metastasis from cutaneous melanoma to the liver: resection by extended left hepatectomy (trisegmentectomy) with clearance of tumor from the portal vein. HPB Surg 1994; 8:53–6PubMed Vauthey JN, Winter MW, Blumgart LH. Solitary metastasis from cutaneous melanoma to the liver: resection by extended left hepatectomy (trisegmentectomy) with clearance of tumor from the portal vein. HPB Surg 1994; 8:53–6PubMed
20.
Zurück zum Zitat Papachristou DN, Fortner JJ. Surgical treatment of metastatic melanoma confined to the liver. Int Surg 1983; 68:145–8PubMed Papachristou DN, Fortner JJ. Surgical treatment of metastatic melanoma confined to the liver. Int Surg 1983; 68:145–8PubMed
21.
Zurück zum Zitat Stoelben E, Sturm J, Schmoll J, Keilholz U, Saeger HD. Resection of solitary liver metastases of malignant melanoma (in German). Chirurg 1995; 66:40–3; discussion 3–4PubMed Stoelben E, Sturm J, Schmoll J, Keilholz U, Saeger HD. Resection of solitary liver metastases of malignant melanoma (in German). Chirurg 1995; 66:40–3; discussion 3–4PubMed
22.
Zurück zum Zitat Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer 2000; 89:1561–8CrossRefPubMed Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer 2000; 89:1561–8CrossRefPubMed
23.
Zurück zum Zitat Fournier GA, Albert DM, Arrigg CA, Cohen AM, Lamping KA, Seddon JM. Resection of solitary metastasis. Approach to palliative treatment of hepatic involvement with choroidal melanoma. Arch Ophthalmol 1984; 102:80–2PubMed Fournier GA, Albert DM, Arrigg CA, Cohen AM, Lamping KA, Seddon JM. Resection of solitary metastasis. Approach to palliative treatment of hepatic involvement with choroidal melanoma. Arch Ophthalmol 1984; 102:80–2PubMed
24.
Zurück zum Zitat Harrison LE, Brennan MF, Newman E, et al. Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery 1997; 121:625–32CrossRefPubMed Harrison LE, Brennan MF, Newman E, et al. Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery 1997; 121:625–32CrossRefPubMed
25.
Zurück zum Zitat Khadra MH, Thompson JF, Milton GW, McCarthy WH. The justification for surgical treatment of metastatic melanoma of the gastrointestinal tract. Surg Gynecol Obstet 1990; 171:413–6PubMed Khadra MH, Thompson JF, Milton GW, McCarthy WH. The justification for surgical treatment of metastatic melanoma of the gastrointestinal tract. Surg Gynecol Obstet 1990; 171:413–6PubMed
26.
Zurück zum Zitat Mosimann F, Fontolliet C, Genton A, Gertsch P, Pettavel J. Resection of metastases to the alimentary tract from malignant melanoma. Int Surg 1982; 67:257–60PubMed Mosimann F, Fontolliet C, Genton A, Gertsch P, Pettavel J. Resection of metastases to the alimentary tract from malignant melanoma. Int Surg 1982; 67:257–60PubMed
27.
Zurück zum Zitat Lejeune FJ, Lienard D, Sales F, Badr-el-Din H. Surgical management of distant melanoma metastases. Semin Surg Oncol 1992; 8:381–91PubMed Lejeune FJ, Lienard D, Sales F, Badr-el-Din H. Surgical management of distant melanoma metastases. Semin Surg Oncol 1992; 8:381–91PubMed
28.
Zurück zum Zitat Haigh PI, Essner R, Wardlaw JC, Stern SL, Morton DL. Long-term survival after complete resection of melanoma metastatic to the adrenal gland. Ann Surg Oncol 1999; 6:633–9CrossRefPubMed Haigh PI, Essner R, Wardlaw JC, Stern SL, Morton DL. Long-term survival after complete resection of melanoma metastatic to the adrenal gland. Ann Surg Oncol 1999; 6:633–9CrossRefPubMed
29.
Zurück zum Zitat Branum GD, Epstein RE, Leight GS, Seigler HF. The role of resection in the management of melanoma metastatic to the adrenal gland. Surgery 1991; 109:127–31PubMed Branum GD, Epstein RE, Leight GS, Seigler HF. The role of resection in the management of melanoma metastatic to the adrenal gland. Surgery 1991; 109:127–31PubMed
30.
Zurück zum Zitat Wong JH, Euhus DM, Morton DL. Surgical resection for metastatic melanoma to the lung. Arch Surg 1988; 123:1091–5PubMed Wong JH, Euhus DM, Morton DL. Surgical resection for metastatic melanoma to the lung. Arch Surg 1988; 123:1091–5PubMed
31.
Zurück zum Zitat Ollila DW, Morton DL. Surgical resection as the treatment of choice for melanoma metastatic to the lung. Chest Surg Clin North Am 1998; 8:183–96 Ollila DW, Morton DL. Surgical resection as the treatment of choice for melanoma metastatic to the lung. Chest Surg Clin North Am 1998; 8:183–96
32.
Zurück zum Zitat Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 1995; 110:119–28; discussion 29PubMed Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg 1995; 110:119–28; discussion 29PubMed
33.
Zurück zum Zitat Schwartz SI. Hepatic resection for noncolorectal nonneuroendocrine metastases. World J Surg 1995; 19:72–5CrossRefPubMed Schwartz SI. Hepatic resection for noncolorectal nonneuroendocrine metastases. World J Surg 1995; 19:72–5CrossRefPubMed
34.
Zurück zum Zitat Foster JH, Lundy J. Liver metastases. Curr Probl Surg 1981; 18:160–202 Foster JH, Lundy J. Liver metastases. Curr Probl Surg 1981; 18:160–202
35.
Zurück zum Zitat Dousei T, Miyata M, Yamaguchi T, Nagaoka M, Takahashi E, Kawashima Y. Rupture of liver metastasis of malignant melanomaa case of hepatic resection. Jpn J Surg 1991; 21:480–4PubMed Dousei T, Miyata M, Yamaguchi T, Nagaoka M, Takahashi E, Kawashima Y. Rupture of liver metastasis of malignant melanomaa case of hepatic resection. Jpn J Surg 1991; 21:480–4PubMed
36.
Zurück zum Zitat Rose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 2001; 136:950–5PubMed Rose DM, Essner R, Hughes TM, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg 2001; 136:950–5PubMed
37.
Zurück zum Zitat Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 1996; 114:107–8PubMed Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol 1996; 114:107–8PubMed
38.
Zurück zum Zitat Nathan FE, Sato T, Hart E, Berd D, Mastrangelo MJ. Response to combination chemotherapy of liver metastases from choroidal melanoma compared with cutaneous melanoma. Program Proceedings, Thirtieth Annual Meeting of the American Society of Clinical Oncology. 1994; 13:396. Nathan FE, Sato T, Hart E, Berd D, Mastrangelo MJ. Response to combination chemotherapy of liver metastases from choroidal melanoma compared with cutaneous melanoma. Program Proceedings, Thirtieth Annual Meeting of the American Society of Clinical Oncology. 1994; 13:396.
39.
40.
Zurück zum Zitat Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 1998; 187:487–93CrossRefPubMed Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg 1998; 187:487–93CrossRefPubMed
Metadaten
Titel
Hepatic Resection for Metastatic Melanoma: Distinct Patterns of Recurrence and Prognosis for Ocular Versus Cutaneous Disease
verfasst von
Timothy M. Pawlik, MD, MPH
Daria Zorzi, MD
Eddie K. Abdalla, MD
Bryan M. Clary, MD
Jeffrey E. Gershenwald, MD
Merrick I. Ross, MD
Thomas A. Aloia, MD
Steven A. Curley, MD
Luis H. Camacho, MD, MPH
Lorenzo Capussotti, MD
Dominique Elias, MD
Jean-Nicolas Vauthey, MD
Publikationsdatum
01.05.2006
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2006
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/ASO.2006.01.016

Weitere Artikel der Ausgabe 5/2006

Annals of Surgical Oncology 5/2006 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.